Aptose Biosciences (APS) Competitors

C$2.28 -0.10 (-4.20%)

As of 05/25/2026 09:30 AM Eastern

APS vs. LTY, ACST, REUN, NEPT, and ATE

Should you buy Aptose Biosciences stock or one of its competitors? MarketBeat compares Aptose Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptose Biosciences include Liberty Biopharma (LTY), Acasti Pharma (ACST), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), and Antibe Therapeutics (ATE). These companies are all part of the "biotechnology" industry.

How does Aptose Biosciences compare to Liberty Biopharma?

Liberty Biopharma (CVE:LTY) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

In the previous week, Liberty Biopharma had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for Liberty Biopharma and 0 mentions for Aptose Biosciences. Liberty Biopharma's average media sentiment score of 0.67 beat Aptose Biosciences' score of 0.00 indicating that Liberty Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liberty Biopharma	Positive
Aptose Biosciences	Neutral

0.0% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liberty Biopharma	N/A	N/A	N/A
Aptose Biosciences	N/A	115.24%	-136.29%

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liberty Biopharma	N/A	N/A	N/A	-C$0.16	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liberty Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aptose Biosciences beats Liberty Biopharma on 5 of the 9 factors compared between the two stocks.

How does Aptose Biosciences compare to Acasti Pharma?

Aptose Biosciences (TSE:APS) and Acasti Pharma (CVE:ACST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acasti Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.0% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Acasti Pharma shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by insiders. Comparatively, 20.3% of Acasti Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aptose Biosciences has a beta of -1.238347, indicating that its stock price is 224% less volatile than the broader market. Comparatively, Acasti Pharma has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Acasti Pharma had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for Acasti Pharma and 0 mentions for Aptose Biosciences. Aptose Biosciences' average media sentiment score of 0.00 equaled Acasti Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Acasti Pharma	Neutral

Aptose Biosciences has a net margin of 0.00% compared to Acasti Pharma's net margin of -455.58%. Aptose Biosciences' return on equity of 115.24% beat Acasti Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Acasti Pharma	-455.58%	-67.58%	-8.25%

Acasti Pharma has higher revenue and earnings than Aptose Biosciences. Acasti Pharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Acasti Pharma	C$2.71M	6.71	-C$10.54M	-C$0.48	N/A

Summary

Acasti Pharma beats Aptose Biosciences on 8 of the 12 factors compared between the two stocks.

How does Aptose Biosciences compare to Reunion Neuroscience?

Aptose Biosciences (TSE:APS) and Reunion Neuroscience (TSE:REUN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Aptose Biosciences has a beta of -1.238347, indicating that its share price is 224% less volatile than the broader market. Comparatively, Reunion Neuroscience has a beta of 4.2, indicating that its share price is 320% more volatile than the broader market.

Reunion Neuroscience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Reunion Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Reunion Neuroscience	C$4.86M	0.00	-C$38.10M	-C$3.30	N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Reunion Neuroscience'saverage media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Reunion Neuroscience	Neutral

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Reunion Neuroscience	N/A	-86.35%	-26.50%

0.0% of Aptose Biosciences shares are held by institutional investors. Comparatively, 50.7% of Reunion Neuroscience shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Comparatively, 34.4% of Reunion Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Given Reunion Neuroscience's higher probable upside, analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reunion Neuroscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Reunion Neuroscience beats Aptose Biosciences on 8 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Aptose Biosciences (TSE:APS) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Given Neptune Wellness Solutions' higher possible upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neptune Wellness Solutions	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aptose Biosciences has higher earnings, but lower revenue than Neptune Wellness Solutions. Aptose Biosciences is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Neptune Wellness Solutions	C$48.80M	0.00	-C$192.95M	-C$24.16	N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Neptune Wellness Solutions'average media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Neptune Wellness Solutions	Neutral

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Neptune Wellness Solutions	N/A	N/A	N/A

0.0% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aptose Biosciences beats Neptune Wellness Solutions on 6 of the 10 factors compared between the two stocks.

How does Aptose Biosciences compare to Antibe Therapeutics?

Antibe Therapeutics (TSE:ATE) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	-52.72%	-19.13%
Aptose Biosciences	N/A	115.24%	-136.29%

Given Antibe Therapeutics' higher possible upside, research analysts clearly believe Antibe Therapeutics is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of Aptose Biosciences shares are held by institutional investors. 7.9% of Antibe Therapeutics shares are held by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Antibe Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Aptose Biosciences has a beta of -1.238347, indicating that its stock price is 224% less volatile than the broader market.

Antibe Therapeutics has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.71M	0.00	-C$18.24M	-C$0.35	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

In the previous week, Antibe Therapeutics' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Antibe Therapeutics	Neutral
Aptose Biosciences	Neutral

Summary

Antibe Therapeutics beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APS vs. The Competition

Export

Metric	Aptose Biosciences	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$6.07M	C$470.59M	C$6.46B	C$12.16B
Dividend Yield	0.39%	3.87%	2.76%	6.20%
P/E Ratio	-0.22	3.86	21.21	37.64
Price / Sales	N/A	7,288.62	554.38	11.68
Price / Cash	1.60	13.13	43.49	82.29
Price / Book	-0.17	84.78	10.37	4.50
Net Income	-C$154.69M	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	-2.15%	0.05%	6.40%	2.48%
1 Month Performance	-2.98%	0.57%	3.53%	1.47%
1 Year Performance	-8.43%	63.42%	34.04%	53.55%

Aptose Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APS Aptose Biosciences	N/A	C$2.28 -4.2%	N/A	-3.4%	C$6.07M	N/A	N/A	31	Gap Down
LTY Liberty Biopharma	N/A	C$2.00 +∞	N/A	+0.0%	C$21.54M	N/A	N/A	N/A	Gap Up
ACST Acasti Pharma	N/A	C$0.58 +1.8%	N/A	+0.0%	C$18.19M	C$2.71M	N/A	32	News Coverage
REUN Reunion Neuroscience	N/A	N/A	N/A	N/A	C$16.64M	C$4.86M	N/A	190	Gap Down
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	C$15.73M	C$48.80M	N/A	130	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:APS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Does the media prefer LTY or APS?

Do insiders and institutionals have more ownership in LTY or APS?

Is LTY or APS more profitable?

Which has better valuation and earnings, LTY or APS?

Do analysts rate LTY or APS?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Do analysts rate APS or ACST?

Do insiders and institutionals hold more shares of APS or ACST?

Which has more volatility and risk, APS or ACST?

Does the media refer more to APS or ACST?

Is APS or ACST more profitable?

Which has better valuation and earnings, APS or ACST?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Which has more volatility & risk, APS or REUN?

Which has preferable valuation and earnings, APS or REUN?

Does the media refer more to APS or REUN?

Is APS or REUN more profitable?

Do insiders & institutionals have more ownership in APS or REUN?

Do analysts rate APS or REUN?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Do analysts recommend APS or NEPT?

Which has preferable earnings and valuation, APS or NEPT?

Does the media favor APS or NEPT?

Is APS or NEPT more profitable?

Do institutionals & insiders hold more shares of APS or NEPT?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Is ATE or APS more profitable?

Do analysts prefer ATE or APS?

Do insiders and institutionals believe in ATE or APS?

Which has more risk & volatility, ATE or APS?

Which has preferable valuation and earnings, ATE or APS?

Does the media prefer ATE or APS?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools